ADIAL PHARMACEUTICALS, INC. (AZR): Form 8-K filed 2026-10-28

Items reported

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed.
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
The company amended its articles of incorporation or bylaws without a shareholder vote that was previously disclosed, or changed its fiscal year.
Item 5.07: Submission of Matters to a Vote of Security Holders
The company reports the results of a shareholder meeting: each matter voted on and the votes cast for, against, abstaining and broker non-votes.
Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Type	Description	Document
8-K	CURRENT REPORT	ea0309977-8k_adial.htm
EX-3.1	CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF	ea030997701ex3-1.htm
EX-99.1	PRESS RELEASE, DATED OCTOBER 28, 2026	ea030997701ex99-1.htm

This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.